|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,820,000 |
Market
Cap: |
163.20(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.62 - $4.13 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
2,292,857 |
Total Buy Value |
$0 |
$0 |
$0 |
$8,025,000 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
0 |
0 |
0 |
160,696 |
Total Sell Value |
$0 |
$0 |
$0 |
$592,808 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Malin Life Sciences Holdings Ltd |
Common director with Issuer |
|
2021-11-30 |
4 |
B |
$6.85 |
$195,838 |
D/D |
28,592 |
9,661,184 |
2.45 |
-39% |
|
Malin Life Sciences Holdings Ltd |
Common director with Issuer |
|
2021-11-18 |
4 |
B |
$7.18 |
$511,685 |
D/D |
71,312 |
9,567,501 |
2.45 |
-35% |
|
Ingalls Kerry D. |
Chief Operating Officer |
|
2021-11-17 |
4 |
B |
$7.00 |
$14,000 |
D/D |
2,000 |
2,000 |
2.74 |
-37% |
|
Malin Life Sciences Holdings Ltd |
Common director with Issuer |
|
2021-11-17 |
4 |
B |
$7.21 |
$2,021,821 |
D/D |
280,384 |
9,496,189 |
2.45 |
-37% |
|
Malin Life Sciences Holdings Ltd |
Common director with Issuer |
|
2021-11-16 |
4 |
B |
$7.17 |
$198,383 |
D/D |
27,680 |
9,215,805 |
2.45 |
-39% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-11-08 |
4 |
AS |
$7.09 |
$134,171 |
I/I |
(18,924) |
3,358,455 |
|
-27% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-10-11 |
4 |
OE |
$9.15 |
$169,504 |
D/D |
18,525 |
696,422 |
|
- |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-10-01 |
4 |
AS |
$7.02 |
$140,604 |
I/I |
(20,029) |
3,367,506 |
|
-44% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-09-20 |
4 |
AS |
$8.00 |
$160,020 |
I/I |
(20,000) |
160,696 |
|
-40% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-09-14 |
4 |
AS |
$8.14 |
$162,712 |
I/I |
(20,000) |
180,696 |
|
-41% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-09-13 |
4 |
OE |
$1.17 |
$172,729 |
D/D |
21,281 |
675,415 |
|
- |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-09-09 |
4 |
OE |
$1.32 |
$13,220 |
D/D |
10,000 |
51,485 |
|
- |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-09-02 |
4 |
AS |
$8.34 |
$510,925 |
I/I |
(61,262) |
3,377,085 |
|
-35% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-09-01 |
4 |
AS |
$8.46 |
$432,721 |
I/I |
(51,149) |
3,406,384 |
|
-30% |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-08-20 |
4 |
AS |
$8.79 |
$35,142 |
D/D |
(4,000) |
41,485 |
|
-24% |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-08-20 |
4 |
OE |
$1.32 |
$5,288 |
D/D |
4,000 |
45,485 |
|
- |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-08-06 |
4 |
OE |
$9.15 |
$1,017,013 |
D/D |
111,149 |
654,134 |
|
- |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-08-03 |
4 |
AS |
$7.99 |
$159,289 |
I/I |
(19,936) |
3,430,847 |
|
-12% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-08-02 |
4 |
AS |
$8.13 |
$111,682 |
I/I |
(13,737) |
3,440,382 |
|
-11% |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-07-28 |
4 |
OE |
$1.32 |
$26,440 |
D/D |
20,000 |
41,485 |
|
- |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-07-02 |
4 |
AS |
$8.90 |
$245,274 |
I/I |
(27,542) |
3,446,952 |
|
-23% |
|
Ostertag Eric |
Chief Executive Officer |
|
2021-07-01 |
4 |
AS |
$9.77 |
$200,901 |
I/I |
(20,563) |
3,460,124 |
|
-31% |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-06-17 |
4 |
OE |
$1.32 |
$6,610 |
D/D |
5,000 |
21,485 |
|
- |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-06-11 |
4 |
AS |
$9.44 |
$37,747 |
D/D |
(4,000) |
16,485 |
|
-33% |
|
Spear Matthew A. |
Chief Medical Officer |
|
2021-06-11 |
4 |
OE |
$1.32 |
$5,288 |
D/D |
4,000 |
20,485 |
|
- |
|
103 Records found
|
|
Page 3 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|